Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease.

Ninon Soufflet,Gilles Boschetti,Xavier Roblin, Charlotte Cuercq,Nicolas Williet,Anne-Laure Charlois,Remi Duclaux-Loras,Pauline Danion,Anne Mialon,Mathias Faure,Stéphane Paul,Bernard Flourie,Stéphane Nancey

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association（2019）

引用 38|浏览32

暂无评分

摘要

Ustekinumab is approved for treatment of Crohn's disease (CD).1,2 Few data are available to assess the usefulness of monitoring inflammatory biomarkers and therapeutic drug monitoring to predict response to ustekinumab. We conducted a prospective study to assess the relationships between these parameters and the clinical outcome at week 16 in active CD patients receiving ustekinumab.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要